WINDTREE THERAPEUTICS INC.

WINDTREE THERAPEUTICS INC.

- USD (-)

- 15 min delayed data - NASDAQ Stocks

Open:	-
Change:	-
Volume:	-

Low:	-
High:	-
High / Low range:	-

Type:	Stocks
Ticker:	WINT
ISIN:

WINDTREE THERAPEUTICS INC. overview

> Analyses

Londinia AI has published a new analysis for aba0550.

0
93495
15793
0

WINDTREE THERAPEUTICS INC. - Daily

WINDTREE THERAPEUTICS INC. - Daily

Timeframe : Daily - Simple chart
Status : INVALID

Has the basic bearish trend slowed or is it lacking in power? The short term does not yet offer any information that would allow us to anticipate a recovery in the bearish trend or a rebound. Sellers'…

Thank you Reply Chart

> Analyses

Londinia AI has published a new analysis for aba0550.

0
93495
15793
0

WINDTREE THERAPEUTICS INC. - 1H

WINDTREE THERAPEUTICS INC. - 1H

Timeframe : 1H - Simple chart
Status : TARGET REACHED

All elements being clearly bullish, it would be possible for traders to trade only long positions (at the time of purchase) on WINDTREE THERAPEUTICS INC. as long as the price remains well above 4.47…

Thank you Reply Chart

> News PR Newswire published a news.

Windtree Receives Notice of Delisting from NASDAQ • • PR Newswire • Stocks • More WINDTREE THERAPEUTICS INC. news...

Windtree Receives Notice of Delisting from NASDAQ - Common Stock to Begin Trading on OTCQB® Market Effective May 5, 2017 - PR Newswire WARRINGTON, Pa., May 3, 2017 WARRINGTON, Pa. , May 3, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has received written notification from the NASDAQ Stock Market ("NASDAQ") that it has determined to delist the...

Thank you Chart

> News PR Newswire published a news.

Windtree Announces Successful Completion of Second and Final AEROSURF® Phase 2b Clinical Trial Interim Safety Review • • PR Newswire • Stocks • More WINDTREE THERAPEUTICS INC. news...

Windtree Announces Successful Completion of Second and Final AEROSURF® Phase 2b Clinical Trial Interim Safety Review -DSMB Recommends Continued Enrollment in AEROSURF Phase 2b Clinical Trial Without Modifications- -Company Remains on Track to Release Phase 2b Results Mid-Year 2017- PR Newswire WARRINGTON, Pa., April 11, 2017 WARRINGTON, Pa. , April 11, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant...

Thank you Chart

> News PR Newswire published a news.

Windtree Therapeutics Reports Fourth Quarter 2016 Financial Results and Provides Key Business Updates • • PR Newswire • Stocks • More WINDTREE THERAPEUTICS INC. news...

Windtree Therapeutics Reports Fourth Quarter 2016 Financial Results and Provides Key Business Updates Company Continues to Advance Phase 2 Program and is On-Track for Mid-Year Phase 2b Results PR Newswire WARRINGTON, Pa., March 31, 2017 WARRINGTON, Pa. , March 31, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today reported financial results for the fourth quarter ended...

Thank you Chart

> News PR Newswire published a news.

Windtree Therapeutics' Aerosolized KL4 Surfactant Reduces Lung Inflammation and Improves Survival in a High-Pathogen Avian Influenza Preclinical Study • • PR Newswire • Stocks • More WINDTREE THERAPEUTICS INC. news...

Windtree Therapeutics' Aerosolized KL4 Surfactant Reduces Lung Inflammation and Improves Survival in a High-Pathogen Avian Influenza Preclinical Study PR Newswire WARRINGTON, Pa., Feb. 16, 2017 WARRINGTON, Pa. , Feb. 16, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focusing on developing aerosolized KL4 surfactant therapies for respiratory diseases, announced today that data from a preclinical influenza study showed that aerosolized KL4 surfactant...

Thank you Chart

> News PR Newswire published a news.

Windtree Therapeutics Completes $10.5 Million Private Offering • • PR Newswire • Stocks • More WINDTREE THERAPEUTICS INC. news...

Windtree Therapeutics Completes $10.5 Million Private Offering Company Now Adequately Funded Through AEROSURF® Phase 2b Data in Mid-2017 PR Newswire WARRINGTON, Pa., Feb. 15, 2017 WARRINGTON, Pa. , Feb. 15, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has completed a $10.5 million private placement of convertible preferred stock units and now...

Thank you Chart

> News PR Newswire published a news.

Windtree Therapeutics to Host a Conference Call and Webcast at 8:00 AM on Thursday, February 16, 2017 to Provide Clinical and Financial Updates • • PR Newswire • Stocks • More WINDTREE THERAPEUTICS INC. news...

Windtree Therapeutics to Host a Conference Call and Webcast at 8:00 AM on Thursday, February 16, 2017 to Provide Clinical and Financial Updates PR Newswire WARRINGTON, Pa., Feb. 15, 2017 WARRINGTON, Pa. , Feb. 15, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (Nasdaq: WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, will host a conference call and webcast (including a slide presentation) at 8:00 AM EST on Thursday, February...

Thank you Chart

Load more content